PCV77 Economic Evaluation of Dabigatran Etexilate 150dib for the Stroke Prevention in Atrial Fibrillation in Greece: A Cost–Effectiveness Analysis under the Greek …
V Fragoulakis, T Theodoratou… - Value in …, 2011 - valueinhealthjournal.com
Objectives To estimate the cost-effectiveness of Dabigatran etexilate 150dib relative to
Sintrom, Aspirin, Aspitin-Clopidogrel, Best Supportive Care and no treatment, in the …
Sintrom, Aspirin, Aspitin-Clopidogrel, Best Supportive Care and no treatment, in the …
PCV53 A Cost-Effectiveness Analysis Comparing Dabigatran and Standard Treatment for Stroke Prevention in Atrial Fibrillation in Slovakia
M Psenkova, S Mackovicova, D Tomek… - Value in …, 2012 - valueinhealthjournal.com
Objectives To compare the costs and effectiveness of dabigatran etexilate with current
standard treatment in patients with non-valvular atrial fibrillation (NVAF), from the Slovakian …
standard treatment in patients with non-valvular atrial fibrillation (NVAF), from the Slovakian …
PCV47 Economic Evaluation of Dabigatran for Stroke Prevention Among Patients With Atrial Fibrillation in the Netherlands
HH Le, P Pechlivanoglou, PM Engelfriet… - Value in …, 2012 - valueinhealthjournal.com
Objectives Patients with atrial fibrillation (AF) are at increased risk of stroke. Furthermore, AF-
related strokes are associated with greater severity, disability, and mortality than strokes of …
related strokes are associated with greater severity, disability, and mortality than strokes of …
PCV60 Cost Effectiveness of Dabigatran Etexilate for Prevention of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Patients in the Turkish Health Care …
S Kececioglu, P Ulus, F Cukadar - Value in Health, 2012 - valueinhealthjournal.com
Objectives To investigate the cost-effectiveness of dabigatran etexilate (dabigatran 150MG)
in the Turkish health care setting. Methods A model was constructed to assess the cost …
in the Turkish health care setting. Methods A model was constructed to assess the cost …
[PDF][PDF] Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece
GK Andrikopoulos, V Fragoulakis… - Hellenic J …, 2013 - researchgate.net
Introduction: The objective of the present study was to evaluate, from an economic
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …
Dabigatran Etexilate in Prevention of Stroke for Nonvalvular Atrial Fibrillation Patients in Turkish Health Care Setting; A Study on Cost Containment of Social Security …
S Kececioglu, P Ulus, F Cukadar, M Ozkan… - Value in …, 2013 - valueinhealthjournal.com
Objectives Analysis of cost containment of SSI via use of Dabigatran Etexilate (150MG)
versus current standard of care (Warfarin) in prevention of stroke for non valvular atrial …
versus current standard of care (Warfarin) in prevention of stroke for non valvular atrial …
Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark
LK Langkilde, M Bergholdt Asmussen… - Journal of Medical …, 2012 - Taylor & Francis
Objective: To estimate the economic implications of introducing dabigatran etexilate
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …
('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial …
Cost-Effectiveness Of Dabigatran For Stroke Prevention In Atrial Fibrillation In China
Y Wan, GM Davies, ZG Lu, F Chen… - Value in Health, 2014 - valueinhealthjournal.com
Objectives Warfarin has been the standard oral anticoagulant for stroke prevention in
patients with atrial fibrillation (AF). However, it has an increased risk of bleeding and a …
patients with atrial fibrillation (AF). However, it has an increased risk of bleeding and a …
PCV50 COST-EFFECTIVENESS ANALYSIS COMPARING DABIGATRAN AND ADJUSTED-DOSE WARFARIN FOR STROKE PREVENTION IN ATRIAL …
Y Zhao, L Lim, CI Coleman - Value in Health, 2011 - valueinhealthjournal.com
Objectives Atrial fibrillation has been estimated to affect as many as 2.3 million Americans,
making it the second most common cardiovascular condition in the United States. Atrial …
making it the second most common cardiovascular condition in the United States. Atrial …
Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
M Pletscher, R Plessow, K Eichler… - Swiss medical …, 2013 - digitalcollection.zhaw.ch
Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …